ArticleBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine2026
Multifunctional auranofin analogues: dual-targeting TSPO/TrxR gold(I) complexes with activity in resistant ovarian cancer.
Article in Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Auranofin (AF) is a clinically approved gold(I) complex used for the treatment of rheumatoid arthritis and currently under investigation for drug repurposing in oncology. Its anticancer activity has been mainly associated with the inhibition of thioredoxin reductase (TrxR), an enzyme crucial for the maintenance of the redox balance of cell. Accordingly, this triggered intense research in the development of novel AF-analogues. Herein, a new series of AF-inspired gold(I) complexes (1-4) was designed and synthesized by replacing the thiosugar moiety with ligands targeting the translocator protein (TSPO), a mitochondrial protein overexpressed in several cancers, including ovarian cancer. The new complexes showed strong TrxR inhibition and sub/low-nanomolar TSPO affinity. All compounds exhibited low-micromolar cytotoxicity in ovarian cancer cells, including cisplatin- and AF-resistant variants, with a milder reduction in activity than AF and cisplatin in resistant models. Computational studies indicated that replacement of the thiosugar moiety with TSPO ligands affects the stability of the Au-S and Au-P bonds, leading to a different activation mode compared with AF. In parallel, ICP-AES analysis revealed comparable intracellular gold accumulation for complexes 1-4 and AF, indicating that differences in biological activity are not mainly driven by cellular uptake, but rather by distinct intracellular processing and target engagement. Overall, these findings support the conjugation of the [Au(PEt
Indexed as
Identifiers
42622984What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.